ClinicalTrials.gg
Not yet recruitingNCT07917468Updated Nov 4, 2026

Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer

A Phase 3 interventional study of Oxaliplatin and Placebo in Locally Advanced Rectal Cancer, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Updated Nov 4, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing sintilimab in Rectal Neoplasms — 13 open to participants now, 16 under way, 5 of them phase 3. sintilimab · Rectal Neoplasms.

Planned enrollment
2nd of 19
500 · median 50
Started
2026
with 6 others
Phase 3
2 of 19
2 open now
Primary completion
2030-03
later than 15 of 15 live
Registered
18th of 19
by date
Lead sponsor
1 of 19
Innovent Biologics (Suzhou) Co. Ltd.

Among the 19 studies testing sintilimab in Rectal Neoplasms, this one is the 2nd largest by planned enrollment, is one of 7 that started in 2026, is one of 2 in phase 3, reaches primary completion later than 15 of the 15 other live ones, and was the 18th registered.

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

13 of the 19 studies testing sintilimab in Rectal Neoplasms are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 405 Rectal Neoplasms studies recruiting now, 210 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing sintilimab in Rectal Neoplasms, or all of them as a file.
02

Study summary

This is a randomized, double-blind, controlled, Phase III clinical study to evaluate the efficacy and safety of sintilimab combined with long-course concurrent chemoradiotherapy followed by Capeox consolidation chemotherapy, which is planned to enroll 500 subjects with locally advanced rectal cancer.

03

Conditions studied

  • Locally Advanced Rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  1. Has signed the written Form and is capable of complying with the visit schedules and relevant procedures specified in the protocol.
  2. Histopathologically confirmed locally advanced rectal adenocarcinoma, with clinical stage cT3-4NanyM0 or cT1-2N1-2M0 as defined by the AJCC 8th edition, and assessed as amenable to R0 resection after therapy. MRI demonstrates that the lower edge of the tumor is within 10 cm from the anal verge.
  3. Tumor pathological tissue testing confirms pMMR, i.e., immunohistochemical staining shows positive expression of all four proteins MLH1, MSH2, MSH6, and PMS2, or tumor tissue-based genetic testing indicates MSI-L or MSS.
  4. No signs of intestinal obstruction; or intestinal obstruction that has been relieved after proximal colostomy.
  5. No prior rectal surgery; no prior systemic anti-cancer therapy, or other drug therapy.
  6. Age ≥18 years, both sexes eligible.
  7. Performance Status (ECOG PS) of 0 or 1.
  8. Expected survival of ≥2 years.
  9. Adequate bone marrow and organ function. Exclusion Criteria

1. Currently participating in another interventional clinical study, except for observational (non-interventional) clinical studies or those in the survival follow-up phase of an interventional study.

2. Plans to receive other anti-tumor therapy during the treatment period of this study.

3. Receipt of any within 4 weeks before the first dose of study drug, or plans to receive any live vaccine during the study period.

4. Presence of toxicity from prior therapy that has not recovered to Grade 0 or 1 per V6.0 before the first dose of study drug (excluding alopecia, fatigue, pigmentation, and other conditions judged by the investigator to pose no safety risk).

5. Major surgery 6. Receipt of therapy within 4 weeks before the first dose of study drug, excluding topical administered intranasally, by inhalation, or by other local routes, or physiological doses of systemic corticosteroids , or corticosteroids used to prevent contrast agent allergy.

7. Recurrent rectal cancer; multiple primary colorectal cancers. 8. History of pelvic or abdominal radiotherapy.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
500 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo combined with long-course concurrent chemoradiotherapy followed by Capeox consolidation chemotherapy

    Drug: Oxaliplatin · Drug: Placebo · Radiation: radiotherapy · Drug: Capecitabine · Procedure: Radical resection of rectal cancer

  • Experimental
    Sintilimab

    sintilimab combined with long-course concurrent chemoradiotherapy followed by Capeox consolidation chemotherapy

    Drug: Oxaliplatin · Radiation: radiotherapy · Drug: Capecitabine · Procedure: Radical resection of rectal cancer · Drug: Sintilimab

Interventions

  • 130 mg/m²,IV,Q3W

  • DrugPlacebo

    20 ml D1 IV Q3W

  • Radiationradiotherapy

    PTV1 50 Gy/25 times, PTV2 45 Gy/25 times, 5 days a week, for a total of 5 weeks (D1-D35)

  • 825 mg/m ² PO BID ,Days 1-5 QW;1000mg/m ² PO BID ,Days 1-14 Q3W;

  • ProcedureRadical resection of rectal cancer

    Radical resection of rectal cancer

  • 200 mg D1 IV Q3W

06

What researchers measure

Primary outcomes

  1. EFS

    EFS refers to the time from randomization to the first occurrence of any of the following events: disease progression precluding surgical treatment, local or distant recurrence, death from any cause, etc.

    Time frame: throutg treatment completion an average of 5 years

Secondary outcomes

  1. OS

    OS is defined as the time from the date of randomization until the date of death from any cause.

    Time frame: throutg treatment completion an average of 5 years

  2. CCR

    CCR defined as the proportion of participants achieving pathological complete response (pCR) or clinical complete response (cCR)

    Time frame: up to 5 years after enrollment

  3. R0 resection rate

    R0 resection rate: Descriptive summary of R0 resection rate

    Time frame: up to 5 years after enrollment

  4. EFS3

    EFS3 defined as the proportion of participants who remain free from any of the following events for 3 years after randomization: disease progression precluding surgery, local or distant recurrence, or death from any cause

    Time frame: 3yaers

  5. TRG

    Pathological assessment of tumor regression grading (TRG) after neoadjuvant therapy

    Time frame: up to 5 years after enrollment

  6. neoadjuvant therapy completion rate

    Neoadjuvant therapy completion rate: Descriptive summary of Neoadjuvant therapy completion rate

    Time frame: up to 5 years after enrollment

  7. OPR

    The definition of organ preservation is: no radical total mesorectal excision (TME) performed, and no local regrowth, unless such regrowth can be salvaged by local excision achieving a limited, radical (R0) resection, with no permanent stoma (including a protective stoma that has never been reversed, or a stoma resulting from adverse events and/or poor functional outcome, or a permanent stoma).

    Time frame: up to 5 years after enrollment

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2030, 40 months later.

Of 81 phase 3 interventional studies under Rectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 95. This study's planned 40 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2026
First posted
Nov 4, 2026
StartEst.
Nov 25, 2026
Primary completionEst.
Mar 25, 2030
CompletionEst.
Nov 24, 2031
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07917468
Responsible party
Sponsor
First posted
Nov 4, 2026
Start date
Nov 25, 2026 (estimated)
Primary completion
Mar 25, 2030 (estimated)
Completion
Nov 24, 2031 (estimated)
Last update
Nov 4, 2026

Study contacts

Yanxi Pu
Contact
yanxi.pu@innoventbio.com
+86-18523197816

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion